See leaflet
Bioponib®
Ponatinib
Indications
- Chronic Myeloid Leukemia (CML) in its different stages known as chronic, accelerated and blast phases. It is recommended for patients who cannot tolerate or do not respond to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not considered appropriate. It is also used in patients who have a genetic mutation called ‘T315I mutation’.
- Acute Lymphoblastic Leukemia (ALL) in patients who are 'Philadelphia-chromosome positive' (Ph+). It is used in patients who cannot tolerate or do not respond to dasatinib and for whom subsequent treatment with imatinib is not considered appropriate. It is also used in patients who have a genetic mutation called ‘T315I mutation’.
Presentations
- 15 mg x 30 tablets
- 15 mg x 60 tablets
- 45 mg x 30 tablets
